Almost half of people who are currently on ORLADEYO® were previously taking another preventative therapy, including an injectablea

Access a guide to use when talking to your doctor about switching

In a clinical study, people who switched to ORLADEYO from an injectable therapy were attack-free for more than 80% of the next 12 months after switching. These same patients reported improved convenience and similar effectiveness as their previous therapy.

aBased on data on file from BioCryst Pharmaceuticals, Inc. Data current as of February 2023.
bThese data are from an analysis of 34 US patients who switched from an injectable prophylaxis to ORLADEYO during a long-term safety study. It is unknown what these patients would have experienced had they remained on injectable prophylaxis.
cAccording to a questionnaire that measures medication satisfaction. The efficacy and safety of ORLADEYO compared with other treatments have not been established.